Glycaemic management of type 2 diabetes

Slides:

Advertisements

Similar presentations

SOD1 Integrates Signals from Oxygen and Glucose to Repress Respiration Amit R. Reddi, Valeria C. Culotta Cell Volume 152, Issue 1, Pages (January.

Advertisements

Adaptation to Natural Binocular Disparities in Primate V1 Explained by a Generalized Energy Model Ralf M. Haefner, Bruce G. Cumming Neuron Volume 57, Issue.

2002 Air Medical Transport Industry Awards Air Medical Journal Volume 22, Issue 2, Pages (March 2003) DOI: /S X(03) Copyright.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Diabetes and Ramadan: Practical guidelines

James Thrasher, MD The American Journal of Medicine

Volume 384, Issue 9961, Pages (December 2014)

Copyright © 2015 by the American Osteopathic Association.

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon? Ronald M. Goldenberg,

Matthew P. Gilbert, DO, MPH, Richard E. Pratley, MD

Dizziness in older adults

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Fig. 3. Plasma profiles of active GIP (A) and total GIP (B) concentrations after administration of single oral doses of sitagliptin 25 (white circles)

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients Chun-Chin Chang, MD, Yung-Tai.

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

Stuart A. Ross, MB CHB, FRACP, FRCP(C)

Alan E. Jones, MD, Michael A. Puskarich, MD

Hepatitis in the traveller

Fever and rash Medicine Volume 46, Issue 1, Pages (January 2018)

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use David M. Kendall, MD, Robert M. Cuddihy, MD,

Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis Patricia M.

EMPA-REG OUTCOME: The Endocrinologist's Point of View

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

James Thrasher, MD The American Journal of Medicine

Statins and type 2 diabetes: genetic studies on target

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Physical activity and prevention of type 2 diabetes

Volume 15, Issue 1, Pages (January 2012)

Dipeptidyl Peptidase-4 Inhibitors, Peripheral Arterial Disease, and Lower Extremity Amputation Risk in Diabetic Patients Chun-Chin Chang, MD, Yung-Tai.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Calendar Annals of Emergency Medicine

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Practice Paper of the American Dietetic Association: A Systems Approach to Measuring Productivity in Health Care Foodservice Operations Journal of.

A New Drug Target for Type 2 Diabetes

Training for the infectious diseases speciality in Norway

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Modern strategies for management of glycaemia in type 1 diabetes

Volume 152, Issue 1, (January 2013)

Hypoglycaemia in diabetes

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Figure 1 Sites of action of glucose-lowering agents

What is type 1 diabetes? Medicine

S8 – S47 and O50 – O440 Clinical Microbiology and Infection

Symposia and Oral Presentations

Glycaemic management in patients with diabetes in hospital

Epidemiology of diabetes

Emerging infectious diseases

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

What is type 2 diabetes? Medicine

Table of contents The Journal for Nurse Practitioners

CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management G. B. John Mancini, MD, Alice.

Organization news Archives of Physical Medicine and Rehabilitation

Glucose-lowering medication in type 2 diabetes: overall approach.

Diabetic ketoacidosis and hyperosmolar crisis in adults

T cells and T-cell receptors in acute renal failure

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

ACRM News Archives of Physical Medicine and Rehabilitation

Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review Venkatesan Thiruvenkatarajan, Emily.

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control.

Renal licences of commonly used anti-diabetes drugs

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Volume 148, Issue 1, (January 2012)

Emerging infectious diseases

Presentation transcript:

Glycaemic management of type 2 diabetes Balasubramanian T. Srinivasan, Melanie Davies Medicine Volume 47, Issue 1, Pages 32-39 (January 2019) DOI: 10.1016/j.mpmed.2018.10.009 Copyright © 2018 Terms and Conditions

Figure 1 DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP1RA, glucagon-like peptide 1 receptor agonist; OAA, oral anti-hyperglycaemic agent; SGLT-2i, sodium glucose co-transporter 2 inhibitor; SU, sulfonylurea. Adapted from NICE.3 Medicine 2019 47, 32-39DOI: (10.1016/j.mpmed.2018.10.009) Copyright © 2018 Terms and Conditions